Sodium Phosphates
Loading...Sodium Phosphates Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
Sodium Phosphates Injection, USP must be diluted and thoroughly mixed before use.
To avoid phosphorus intoxication, infuse solutions containing sodium phosphate slowly. Infusing high concentrations of phosphorus may result in a reduction of serum calcium and symptoms of hypocalcemic tetany. Calcium levels should be monitored.
Solutions containing sodium ion should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention.
In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particulary at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
Sodium Phosphates Injection, USP, 3mM P/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte content of such prepared solutions.
History
There is currently no drug history available for this drug.
Other Information
Sodium Phosphates Injection, USP is a sterile, nonpyrogenic, concentrated solution containing a mixture of monobasic and dibasic sodium phosphate in Water for Injection. It must be diluted prior to administration.
Each mL of the solution consists of two phosphate salts provided as follows:
| Ingredient (s) | Phosphorus | Sodium |
| Monobasic Sodium Phosphate Monohydrate - 276 mg |
93 mg or |
92 mg or |
| Dibasic Sodium Phosphate Anhydrous – 142 mg |
3 mM |
4 mEq |
The solution contains no bacteriostatic agent or other preservative.
The solution is intended to provide phosphate ion: (PO4-3) for addition to large volume infusion fluids for intravenous use. Unused portions should be discarded.
Sources
Sodium Phosphates Manufacturers
-
American Regent, Inc.
![Sodium Phosphates (Sodium Phosphate, Monobasic, Monohydrate And Sodium Phosphate, Dibasic Anhydrous) Injection, Solution [American Regent, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Sodium Phosphates | American Regent, Inc.
Sodium Phosphates Injection, USP is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage.
Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluid to provide the desired number of millimoles (mM) of phosphorus and milliequivalents (mEq) of sodium.
-
Cardinal Health
Sodium Phosphates | Cardinal Health
Sodium Phosphates Injection, USP is administered intravenously only after dilution in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage.
Withdraw the calculated volume aseptically and transfer to appropriate intravenous fluid to provide the desired number of millimoles (mM) of phosphorus and milliequivalents (mEq) of sodium.
-
Fresenius Kabi Usa, Llc
Sodium Phosphates | Fresenius Kabi Usa, Llc
Sodium Phosphates Injection is administered intravenously only after dilution and thorough mixing in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, inorganic phosphorus and calcium levels should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of millimoles of phosphate and milli-equivalents of sodium.
In patients on TPN, approximately 10 to 15 mmol of phosphorus (equivalent to 310 to 465 mg elemental phosphorus) per liter bottle of TPN solution is usually adequate to maintain normal serum phosphate, though larger amounts may be required in hypermetabolic states. The amount of sodium which accompanies the addition of phosphate also should be kept in mind, and if necessary, serum sodium levels should be monitored.
The suggested dose of phosphorus for infants receiving TPN is 1.5 to 2 mmol/kg/day.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
-
Hospira, Inc.
Sodium Phosphates | Hospira, Inc.
Sodium Phosphates Injection, USP, 3 mM P/mL is administered intravenously only after dilution and thorough mixing in a larger volume of fluid. The dose and rate of administration are dependent upon the individual needs of the patient. Serum sodium, phosphorus and calcium levels should be monitored as a guide to dosage. Using aseptic technique, all or part of the contents of one or more vials may be added to other intravenous fluids to provide any desired number of millimoles (mM) of phosphorus.
In patients on total parenteral nutrition, approximately 12 to 15 mM of phosphorus (equivalent to 372 to 465 mg elemental phosphorus) per liter bottle of TPN solution containing 250 g dextrose is usually adequate to maintain normal serum phosphorus, though larger amounts may be required in hypermetabolic states. The amount of sodium and phosphorus which accompanies the addition of sodium phosphate also should be kept in mind, and if necessary, serum sodium levels should be monitored.
The suggested dose of phosphorus for infants receiving TPN is 1.5 to 2 mM P/kg/day.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.
![Sodium Phosphates (Sodium Phosphate, Monobasic, Monohydrate And Sodium Phosphate, Dibasic Anhydrous) Injection, Solution [Cardinal Health]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=3d066575-f361-4fcc-b1f3-3ae2be447719&name=3d066575-f361-4fcc-b1f3-3ae2be447719-01.jpg)
![Sodium Phosphates (Sodium Phosphate, Monobasic, Monohydrate) Injection, Solution [Fresenius Kabi Usa, Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e6169d3b-39d2-47f9-8d5b-b53ec069a722&name=sodium-phosphates-injection-usp-figure-2-17015px-vial.jpg)
![Sodium Phosphates (Sodium Phosphate, Monobasic, Monohydrate And Sodium Phosphate, Dibasic, Anhydrous) Injection, Solution [Hospira, Inc.]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6f044d16-295e-43ff-72a3-b045c387bc5c&name=sodium-phosphates-injection-usp1-figure-1-jRL-0580.jpg)
Login To Your Free Account